Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes, with the approval of eight new drugs by the Food and Drug Administration (FDA) within the last 2 years, providing new opportunities, as well as new challenges, for treating clinicians. These therapies include FLT3 inhibitors midostaurin and gilteritinib, CPX-351 (liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin (GO, anti-CD33 monoclonal antibody conjugated with calicheamicin), IDH1/IDH2 inhibitors ivosidenib and enasidenib, Hedgehog inhibitor glasdegib, and BCL-2 inhibitor venetoclax. In this review, we summarize currently available data on these new drugs and discuss the rapidly evolving therapeutic armamentarium for AML, focusing on targeted therapies.

The Time Has Come for Targeted Therapies for AML: Lights and Shadows / Fiorentini, Alessandro; Capelli, Debora; Saraceni, Francesco; Menotti, Diego; Poloni, Antonella; Olivieri, Attilio. - In: ONCOLOGY AND THERAPY. - ISSN 2366-1070. - 8:1(2020), pp. 13-32. [10.1007/s40487-019-00108-x]

The Time Has Come for Targeted Therapies for AML: Lights and Shadows

Alessandro Fiorentini;Francesco Saraceni;Diego Menotti;Antonella Poloni;Attilio Olivieri
Ultimo
2020-01-01

Abstract

Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes, with the approval of eight new drugs by the Food and Drug Administration (FDA) within the last 2 years, providing new opportunities, as well as new challenges, for treating clinicians. These therapies include FLT3 inhibitors midostaurin and gilteritinib, CPX-351 (liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin (GO, anti-CD33 monoclonal antibody conjugated with calicheamicin), IDH1/IDH2 inhibitors ivosidenib and enasidenib, Hedgehog inhibitor glasdegib, and BCL-2 inhibitor venetoclax. In this review, we summarize currently available data on these new drugs and discuss the rapidly evolving therapeutic armamentarium for AML, focusing on targeted therapies.
2020
File in questo prodotto:
File Dimensione Formato  
Fiorentini_The-time-has-come_VoR_2020.pdf

accesso aperto

Tipologia: Documento in post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza d'uso: Creative commons
Dimensione 802.13 kB
Formato Adobe PDF
802.13 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/284340
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 29
social impact